Agitation clinical trials at UCSD

1 research study open to eligible people

BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
open to eligible people ages 55-90
This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.
La Jolla, California and other locations

Last updated: November 21, 2025